These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 4421041)

  • 1. Clinical studies of dopaminergic mechanisms.
    Chase TN
    Adv Biochem Psychopharmacol; 1974; 12(0):427-34. PubMed ID: 4421041
    [No Abstract]   [Full Text] [Related]  

  • 2. Proceedings: Clinical studies of dopaminergic mechanisms.
    Chase TN
    Psychopharmacol Bull; 1974 Jul; 10(3):43-4. PubMed ID: 4419336
    [No Abstract]   [Full Text] [Related]  

  • 3. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
    Rinne UK; Sonninen V; Marttila R
    Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic nervous transmission in Parkinson's disease.
    Rinne UK; Sonninen V; Riekkinen P; Laaksonen H
    Med Biol; 1974 Jun; 52(3):208-17. PubMed ID: 4371255
    [No Abstract]   [Full Text] [Related]  

  • 5. Dopaminergic mechanisms in patients with extrapyramidal disease.
    Chase TN; Shoulson I
    Adv Neurol; 1975; 9():359-66. PubMed ID: 1146660
    [No Abstract]   [Full Text] [Related]  

  • 6. The probenecid test in Parkinson's disease.
    Lakke JP; Korf J; Hoorntje S; Schut T; van Praag HM
    Psychiatr Neurol Neurochir; 1973; 76(2):139-46. PubMed ID: 4700931
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of dopaminergic receptor stimulating agent (Pribedil, ET 495) in Parkinson's disease.
    Lieberman A; Le Brun Y; Boal D; Zolfaghari M
    Adv Biochem Psychopharmacol; 1974; 12(0):415-25. PubMed ID: 4425258
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 9. [Biochemical and clinical correlations in Parkinson's disease].
    Barbeau A
    Rev Neurol (Paris); 1972 Aug; 127(2):253-64. PubMed ID: 4603361
    [No Abstract]   [Full Text] [Related]  

  • 10. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
    Yokochi M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Parkinson's disease: neuro-anatomical, biochemical and pharmicotherapeutic aspects].
    Korf J; van Praagen HM; Lakke JP
    Ned Tijdschr Geneeskd; 1975 Sep; 119(36):1373-8. PubMed ID: 241026
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanisms compensating for dopamine loss in early Parkinson disease.
    Brotchie J; Fitzer-Attas C
    Neurology; 2009 Feb; 72(7 Suppl):S32-8. PubMed ID: 19221312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism.
    McLellan DL; Chalmers RJ; Johnson RH
    Acta Neurol Scand; 1975 Jan; 51(1):74-82. PubMed ID: 1091122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF GABA levels in Parkinson's disease.
    de Jong PJ; Lakke JP; Teelken AW
    Adv Neurol; 1984; 40():427-30. PubMed ID: 6695622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amine precursors in neurologic disorders and the psychoses.
    Klawans H
    Res Publ Assoc Res Nerv Ment Dis; 1975; 54():259-76. PubMed ID: 130667
    [No Abstract]   [Full Text] [Related]  

  • 17. Brain dopamine turnover and the relief of parkinsonism.
    Rinne UK; Sonninen V; Marttila R
    Adv Exp Med Biol; 1977; 90():267-75. PubMed ID: 930747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central monoamine metabolism in man. Effect of putative dopamine receptor agonists and antagonists.
    Chase TN
    Arch Neurol; 1973 Nov; 29(5):349-51. PubMed ID: 4270339
    [No Abstract]   [Full Text] [Related]  

  • 19. [Value of the probenecid test in the diagnosis and treatment of parkinson disease].
    Vanderheyden JE; Noel G; Mendlewicz J
    Acta Neurol Belg; 1982; 82(6):339-52. PubMed ID: 7164768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homovanillic acid in the cerebrospinal fluid of Parkinsonian patients.
    Cunha L; Gonçalves AF; Oliveira C; Dinis M; Amaral R
    Can J Neurol Sci; 1983 Feb; 10(1):43-6. PubMed ID: 6839227
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.